

# SAFETY DATA SHEET



RANCH EXKLUSIV - All variants

## SECTION 1: Identification of the substance/mixture and of the company/undertaking

### 1.1 Product identifier

**Product name** : RANCH EXKLUSIV - All variants

### 1.2 Relevant identified uses of the substance or mixture and uses advised against

**Product use** : Paint.

### 1.3 Details of the supplier of the safety data sheet

Teknos Group Oy, Takkatie 3, FI-00370 HELSINKI, FINLAND. Tel. +358 9 506 091.

**e-mail address of person responsible for this SDS** : Prod-safe@teknos.com

#### National contact

Teknos Ireland Limited, 52 Ballymoughan Road, Magherafelt, BT45 6HN, UK. Tel. +44 (0) 2879 301 472.

### 1.4 Emergency telephone number

#### National advisory body/Poison Centre

**Telephone number** : NHS: 111

## SECTION 2: Hazards identification

### 2.1 Classification of the substance or mixture

**Product definition** : Mixture

#### Classification according to Regulation (EC) No. 1272/2008 [CLP/GHS]

Not classified.

The product is not classified as hazardous according to Regulation (EC) 1272/2008 as amended.

See Section 11 for more detailed information on health effects and symptoms.

### 2.2 Label elements

**Signal word** : No signal word.

**Hazard statements** : No known significant effects or critical hazards.

#### Precautionary statements

**Prevention** : Not applicable.

**Response** : Not applicable.

**Storage** : Not applicable.

**Disposal** : Not applicable.

**Supplemental label elements** : Contains 1,2-benzisothiazol-3(2H)-one, reaction mass of: 5-chloro-2-methyl-4-isothiazolin-3-one [EC no. 247-500-7] and 2-methyl-2H-isothiazol-3-one [EC no. 220-239-6] (3:1) and 2-Methyl-1,2-benzisothiazol-3(2H)-one. May produce an allergic reaction.

Safety data sheet available on request.

Warning! Hazardous respirable droplets may be formed when sprayed. Do not breathe spray or mist. Contains biocidal products for dry film and in-can preservation: IPBC and BIT and DTBMA and MBIT. Risk of skin sensitisation.

## SECTION 2: Hazards identification

Annex XVII - Restrictions :  
on the manufacture,  
placing on the market and  
use of certain dangerous  
substances, mixtures and  
articles

### 2.3 Other hazards

Product meets the criteria for PBT or vPvB according to Regulation (EC) No. 1907/2006, Annex XIII : This mixture does not contain any substances that are assessed to be a PBT or a vPvB.

Other hazards which do not result in classification : None known.

## SECTION 3: Composition/information on ingredients

### 3.2 Mixtures : Mixture

| Product/ingredient name                                                                                                               | Identifiers                                                      | %         | Classification                                                                                                                                                                                 | Specific Conc. Limits, M-factors and ATEs                                                                                                                                                                                                                                   | Type    |
|---------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------|
| titanium dioxide                                                                                                                      | REACH #:<br>01-2119489379-17<br>EC: 236-675-5<br>CAS: 13463-67-7 | ≥10 - ≤25 | Carc. 2, H351<br>(inhalation)                                                                                                                                                                  | -                                                                                                                                                                                                                                                                           | [1] [*] |
| 1,2-benzisothiazol-3(2H)-one                                                                                                          | EC: 220-120-9<br>CAS: 2634-33-5<br>Index: 613-088-00-6           | <0.036    | Acute Tox. 4, H302<br>Acute Tox. 2, H330<br>Skin Irrit. 2, H315<br>Eye Dam. 1, H318<br>Skin Sens. 1A, H317<br>Aquatic Acute 1, H400<br>Aquatic Chronic 1, H410                                 | ATE [Oral] = 450 mg/kg<br>ATE [Inhalation (dusts and mists)] = 0.21 mg/l<br>Skin Sens. 1, H317: C ≥ 0.036%<br>M [Acute] = 1<br>M [Chronic] = 1                                                                                                                              | [1]     |
| reaction mass of: 5-chloro-2-methyl-4-isothiazolin-3-one [EC no. 247-500-7] and 2-methyl-2H-isothiazol-3-one [EC no. 220-239-6] (3:1) | EC: 911-418-6<br>CAS: 55965-84-9<br>Index: 613-167-00-5          | <0.001    | Acute Tox. 3, H301<br>Acute Tox. 2, H310<br>Acute Tox. 2, H330<br>Skin Corr. 1C, H314<br>Eye Dam. 1, H318<br>Skin Sens. 1A, H317<br>Aquatic Acute 1, H400<br>Aquatic Chronic 1, H410<br>EUH071 | ATE [Oral] = 53 mg/kg<br>ATE [Dermal] = 50 mg/kg<br>ATE [Inhalation (vapours)] = 0.5 mg/l<br>Skin Corr. 1C, H314: C ≥ 0.6%<br>Eye Dam. 1, H318: C ≥ 0.6%<br>Eye Irrit. 2, H319: 0.06% ≤ C < 0.6%<br>Skin Sens. 1, H317: C ≥ 0.0015%<br>M [Acute] = 100<br>M [Chronic] = 100 | [1]     |
| 2-Methyl-1,2-benzisothiazol-3(2H)-one                                                                                                 | EC: 695-989-4<br>CAS: 2527-66-4<br>Index: 613-336-00-3           | <0.0015   | Acute Tox. 3, H301<br>Acute Tox. 4, H312<br>Skin Corr. 1C, H314<br>Eye Dam. 1, H318<br>Skin Sens. 1A, H317<br>Aquatic Acute 1, H400<br>Aquatic Chronic 2, H411<br>EUH071                       | ATE [Oral] = 175 mg/kg<br>ATE [Dermal] = 1100 mg/kg<br>Skin Sens. 1, H317: C ≥ 0.0015%<br>M [Acute] = 1                                                                                                                                                                     | [1]     |

## SECTION 3: Composition/information on ingredients

|  |  |  |                                                                      |  |  |
|--|--|--|----------------------------------------------------------------------|--|--|
|  |  |  | See Section 16 for the full text of the H statements declared above. |  |  |
|--|--|--|----------------------------------------------------------------------|--|--|

There are no additional ingredients present which, within the current knowledge of the supplier and in the concentrations applicable, are classified as hazardous to health or the environment, are PBTs, vPvBs or Substances of equivalent concern, or have been assigned a workplace exposure limit and hence require reporting in this section.

### Type

[1] Substance classified with a health or environmental hazard

[\*] The classification as a carcinogen by inhalation applies only to mixtures placed on the market in powder form containing 1% or more of titanium dioxide particles with aerodynamic diameter  $\leq 10 \mu\text{m}$  not bound within a matrix.

Occupational exposure limits, if available, are listed in Section 8.

## SECTION 4: First aid measures

### 4.1 Description of first aid measures

- Eye contact** : Immediately flush eyes with plenty of water, occasionally lifting the upper and lower eyelids. Check for and remove any contact lenses. Get medical attention if irritation occurs.
- Inhalation** : Remove victim to fresh air and keep at rest in a position comfortable for breathing. Get medical attention if symptoms occur.
- Skin contact** : Flush contaminated skin with plenty of water. Remove contaminated clothing and shoes. Get medical attention if symptoms occur.
- Ingestion** : Wash out mouth with water. If material has been swallowed and the exposed person is conscious, give small quantities of water to drink. Do not induce vomiting unless directed to do so by medical personnel. Get medical attention if symptoms occur.
- Protection of first-aiders** : No action shall be taken involving any personal risk or without suitable training.

### 4.2 Most important symptoms and effects, both acute and delayed

#### Over-exposure signs/symptoms

- Eye contact** : No specific data.
- Inhalation** : No specific data.
- Skin contact** : No specific data.
- Ingestion** : No specific data.

### 4.3 Indication of any immediate medical attention and special treatment needed

- Notes to physician** : Treat symptomatically. Contact poison treatment specialist immediately if large quantities have been ingested or inhaled.
- Specific treatments** : No specific treatment.

## SECTION 5: Firefighting measures

### 5.1 Extinguishing media

- Suitable extinguishing media** : Use an extinguishing agent suitable for the surrounding fire.
- Unsuitable extinguishing media** : None known.

### 5.2 Special hazards arising from the substance or mixture

- Hazards from the substance or mixture** : In a fire or if heated, a pressure increase will occur and the container may burst.
- Hazardous combustion products** : Decomposition products may include the following materials:  
carbon dioxide  
carbon monoxide  
metal oxide/oxides

## SECTION 5: Firefighting measures

### 5.3 Advice for firefighters

- Special protective actions for fire-fighters** : Promptly isolate the scene by removing all persons from the vicinity of the incident if there is a fire. No action shall be taken involving any personal risk or without suitable training.
- Special protective equipment for fire-fighters** : Fire-fighters should wear appropriate protective equipment and self-contained breathing apparatus (SCBA) with a full face-piece operated in positive pressure mode. Clothing for fire-fighters (including helmets, protective boots and gloves) conforming to European standard EN 469 will provide a basic level of protection for chemical incidents.

## SECTION 6: Accidental release measures

### 6.1 Personal precautions, protective equipment and emergency procedures

- For non-emergency personnel** : No action shall be taken involving any personal risk or without suitable training. Evacuate surrounding areas. Keep unnecessary and unprotected personnel from entering. Do not touch or walk through spilt material. Put on appropriate personal protective equipment.
- For emergency responders** : If specialised clothing is required to deal with the spillage, take note of any information in Section 8 on suitable and unsuitable materials. See also the information in "For non-emergency personnel".

- 6.2 Environmental precautions** : Avoid dispersal of spilt material and runoff and contact with soil, waterways, drains and sewers. Inform the relevant authorities if the product has caused environmental pollution (sewers, waterways, soil or air).

### 6.3 Methods and material for containment and cleaning up

- Small spill** : Stop leak if without risk. Move containers from spill area. Absorb with an inert material and place in an appropriate waste disposal container. Dispose of via a licensed waste disposal contractor.
- Large spill** : Stop leak if without risk. Move containers from spill area. Prevent entry into sewers, water courses, basements or confined areas. Wash spillages into an effluent treatment plant or proceed as follows. Dispose of via a licensed waste disposal contractor. Contain and collect spillage with non-combustible, absorbent material e. g. sand, earth, vermiculite or diatomaceous earth and place in container for disposal according to local regulations.

- 6.4 Reference to other sections** : See Section 1 for emergency contact information.  
See Section 8 for information on appropriate personal protective equipment.  
See Section 13 for additional waste treatment information.

## SECTION 7: Handling and storage

The information in this section contains generic advice and guidance. The list of Identified Uses in Section 1 should be consulted for any available use-specific information provided in the Exposure Scenario(s).

### 7.1 Precautions for safe handling

- Protective measures** : Put on appropriate personal protective equipment (see Section 8).
- Advice on general occupational hygiene** : Eating, drinking and smoking should be prohibited in areas where this material is handled, stored and processed. Workers should wash hands and face before eating, drinking and smoking. Remove contaminated clothing and protective equipment before entering eating areas. See also Section 8 for additional information on hygiene measures.

### 7.2 Conditions for safe storage, including any incompatibilities

Do not store below the following temperature: 5°C (41°F). Store in accordance with local regulations. Store in original container protected from direct sunlight in a dry, cool and well-ventilated area, away from incompatible materials (see Section 10) and food and drink. Keep container tightly closed and sealed until ready for use. Containers that have been opened must be carefully resealed and kept upright to prevent leakage. Do not store in unlabelled containers. Use appropriate containment to avoid environmental contamination. See Section 10 for incompatible materials before handling or use.

### 7.3 Specific end use(s)

## SECTION 7: Handling and storage

**Recommendations** : Not available.

**Industrial sector specific solutions** : Not available.

## SECTION 8: Exposure controls/personal protection

The information in this section contains generic advice and guidance. Information is provided based on typical anticipated uses of the product. Additional measures might be required for bulk handling or other uses that could significantly increase worker exposure or environmental releases.

### 8.1 Control parameters

#### Occupational exposure limits

| Product/ingredient name        | Exposure limit values |
|--------------------------------|-----------------------|
| No exposure limit value known. |                       |

#### Biological exposure indices

| Product/ingredient name    | Exposure indices |
|----------------------------|------------------|
| No exposure indices known. |                  |

**Recommended monitoring procedures** : Reference should be made to monitoring standards, such as the following: European Standard EN 689 (Workplace atmospheres - Guidance for the assessment of exposure by inhalation to chemical agents for comparison with limit values and measurement strategy) European Standard EN 14042 (Workplace atmospheres - Guide for the application and use of procedures for the assessment of exposure to chemical and biological agents) European Standard EN 482 (Workplace atmospheres - General requirements for the performance of procedures for the measurement of chemical agents) Reference to national guidance documents for methods for the determination of hazardous substances will also be required.

#### DNELs/DMELs

| Product/ingredient name                                                                                                               | Result                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|---------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| titanium dioxide                                                                                                                      | <b>DNEL - General population - Long term - Inhalation</b><br>28 µg/m <sup>3</sup><br><u>Effects</u> : Local<br><br><b>DNEL - Workers - Long term - Inhalation</b><br>170 µg/m <sup>3</sup><br><u>Effects</u> : Local                                                                                                                                                                                                                              |
| 1,2-benzisothiazol-3(2H)-one                                                                                                          | <b>DNEL - General population - Long term - Dermal</b><br>0.345 mg/kg bw/day<br><u>Effects</u> : Systemic<br><br><b>DNEL - Workers - Long term - Dermal</b><br>0.966 mg/kg bw/day<br><u>Effects</u> : Systemic<br><br><b>DNEL - General population - Long term - Inhalation</b><br>1.2 mg/m <sup>3</sup><br><u>Effects</u> : Systemic<br><br><b>DNEL - Workers - Long term - Inhalation</b><br>6.81 mg/m <sup>3</sup><br><u>Effects</u> : Systemic |
| reaction mass of: 5-chloro-2-methyl-4-isothiazolin-3-one [EC no. 247-500-7] and 2-methyl-2H-isothiazol-3-one [EC no. 220-239-6] (3:1) | <b>DNEL - General population - Long term - Inhalation</b><br>0.02 mg/m <sup>3</sup><br><u>Effects</u> : Local<br><br><b>DNEL - Workers - Long term - Inhalation</b><br>0.02 mg/m <sup>3</sup><br><u>Effects</u> : Local                                                                                                                                                                                                                           |

## SECTION 8: Exposure controls/personal protection

### DNEL - General population - Short term - Inhalation

0.04 mg/m<sup>3</sup>

Effects: Local

### DNEL - Workers - Short term - Inhalation

0.04 mg/m<sup>3</sup>

Effects: Local

### DNEL - General population - Long term - Oral

0.09 mg/kg bw/day

Effects: Systemic

### DNEL - General population - Short term - Oral

0.11 mg/kg bw/day

Effects: Systemic

### PNECs

Not available.

## 8.2 Exposure controls

**Appropriate engineering controls** : Good general ventilation should be sufficient to control worker exposure to airborne contaminants.

### Individual protection measures

**Hygiene measures** : Wash hands, forearms and face thoroughly after handling chemical products, before eating, smoking and using the lavatory and at the end of the working period. Appropriate techniques should be used to remove potentially contaminated clothing. Wash contaminated clothing before reusing. Ensure that eyewash stations and safety showers are close to the workstation location.

**Eye/face protection** : Safety eyewear complying with an approved standard should be used when a risk assessment indicates this is necessary to avoid exposure to liquid splashes, mists, gases or dusts. If contact is possible, the following protection should be worn, unless the assessment indicates a higher degree of protection: safety glasses with side-shields.

### Skin protection

**Hand protection** : Chemical-resistant, impervious gloves complying with an approved standard should be worn at all times when handling chemical products if a risk assessment indicates this is necessary.

Recommendations : Wear suitable gloves tested to EN374.

> 8 hours (breakthrough time): Nitrile gloves. thickness > 0.3 mm

Not recommended polyvinyl alcohol (PVA) gloves

**Body protection** : Personal protective equipment for the body should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product.

**Other skin protection** : Appropriate footwear and any additional skin protection measures should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product.

**Respiratory protection** : Based on the hazard and potential for exposure, select a respirator that meets the appropriate standard or certification. Respirators must be used according to a respiratory protection program to ensure proper fitting, training, and other important aspects of use.

Filter type (spray application): A P

**Environmental exposure controls** : Emissions from ventilation or work process equipment should be checked to ensure they comply with the requirements of environmental protection legislation. In some cases, fume scrubbers, filters or engineering modifications to the process equipment will be necessary to reduce emissions to acceptable levels.

## SECTION 9: Physical and chemical properties

The conditions of measurement of all properties are at standard temperature and pressure unless otherwise indicated.

### 9.1 Information on basic physical and chemical properties

#### Appearance

|                                         |                  |
|-----------------------------------------|------------------|
| Physical state                          | : Liquid.        |
| Colour                                  | : Various        |
| Odour                                   | : Slight         |
| Odour threshold                         | : Not available. |
| Melting point/freezing point            | : Not available. |
| Initial boiling point and boiling range | :                |

| Ingredient name  | °C    | °F    | Method |
|------------------|-------|-------|--------|
| water            | 100   | 212   |        |
| Propylene glycol | 188.2 | 370.8 |        |

|                                 |                                                                     |
|---------------------------------|---------------------------------------------------------------------|
| Flammability                    | : Not available.                                                    |
| Lower and upper explosion limit | : Lower: 2.6% (propane-1,2-diol)<br>Upper: 12.6% (propane-1,2-diol) |
| Flash point                     | : Closed cup: >100°C (>212°F)                                       |
| Auto-ignition temperature       | :                                                                   |

| Ingredient name  | °C  | °F    | Method |
|------------------|-----|-------|--------|
| Propylene glycol | 371 | 699.8 |        |

|                           |                  |
|---------------------------|------------------|
| Decomposition temperature | : Not available. |
| pH                        | : 8.5 to 9.1     |
| Viscosity                 | : Not available. |
| Solubility(ies)           | :                |
|                           | Not available.   |

|                                         |                   |
|-----------------------------------------|-------------------|
| Solubility in water                     | : Not available.  |
| Partition coefficient: n-octanol/ water | : Not applicable. |
| Vapour pressure                         | :                 |

| Ingredient name  | Vapour Pressure at 20°C |      |        | Vapour pressure at 50°C |     |        |
|------------------|-------------------------|------|--------|-------------------------|-----|--------|
|                  | mm Hg                   | kPa  | Method | mm Hg                   | kPa | Method |
| water            | 17.5                    | 2.3  |        |                         |     |        |
| Propylene glycol | 0.15                    | 0.02 | EU A.4 |                         |     |        |

|                          |                         |
|--------------------------|-------------------------|
| Relative density         | : Not available.        |
| Density                  | : 1.2 g/cm <sup>3</sup> |
| Vapour density           | : Not available.        |
| Particle characteristics |                         |
| Median particle size     | : Not applicable.       |

### 9.2 Other information

#### 9.2.1 Information with regard to physical hazard classes

|                      |                  |
|----------------------|------------------|
| Explosive properties | : Not available. |
| Oxidising properties | : Not available. |

#### 9.2.2 Other safety characteristics

Not applicable.

## SECTION 10: Stability and reactivity

- 10.1 Reactivity** : No specific test data related to reactivity available for this product or its ingredients.
- 10.2 Chemical stability** : The product is stable.
- 10.3 Possibility of hazardous reactions** : Under normal conditions of storage and use, hazardous reactions will not occur.
- 10.4 Conditions to avoid** : No specific data.
- 10.5 Incompatible materials** : No specific data.
- 10.6 Hazardous decomposition products** : Under normal conditions of storage and use, hazardous decomposition products should not be produced.

## SECTION 11: Toxicological information

### 11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008

#### Acute toxicity

##### **Product/ingredient name**

1,2-benzisothiazol-3(2H)-one

##### **Result**

**Rat - Oral - LD50**

1020 mg/kg

reaction mass of: 5-chloro-2-methyl-4-isothiazolin-3-one [EC no. 247-500-7] and 2-methyl-2H-isothiazol-3-one [EC no. 220-239-6] (3:1)

**Rat - Oral - LD50**

53 mg/kg

Toxic effects: Behavioral - Somnolence (general depressed activity) Behavioral - Ataxia Lung, Thorax, or Respiration - Respiratory depression

**Conclusion/Summary [Product]** : Not available.

#### **Acute toxicity estimates**

| Product/ingredient name                                                                                                               | Oral (mg/kg) | Dermal (mg/kg) | Inhalation (gases) (ppm) | Inhalation (vapours) (mg/l) | Inhalation (dusts and mists) (mg/l) |
|---------------------------------------------------------------------------------------------------------------------------------------|--------------|----------------|--------------------------|-----------------------------|-------------------------------------|
| 1,2-benzisothiazol-3(2H)-one                                                                                                          | 450          | N/A            | N/A                      | N/A                         | 0.21                                |
| reaction mass of: 5-chloro-2-methyl-4-isothiazolin-3-one [EC no. 247-500-7] and 2-methyl-2H-isothiazol-3-one [EC no. 220-239-6] (3:1) | 53           | 50             | N/A                      | 0.5                         | N/A                                 |
| 2-Methyl-1,2-benzisothiazol-3(2H)-one                                                                                                 | 175          | 1100           | N/A                      | N/A                         | N/A                                 |

#### Skin corrosion/irritation

##### **Product/ingredient name**

titanium dioxide

##### **Result**

**Human - Skin - Mild irritant**

Duration of treatment/exposure: 72 hours

Amount/concentration applied: 300 ug l

1,2-benzisothiazol-3(2H)-one

**Human - Skin - Mild irritant**

Duration of treatment/exposure: 48 hours

Amount/concentration applied: 5 %

reaction mass of: 5-chloro-2-methyl-4-isothiazolin-3-one [EC no. 247-500-7] and 2-methyl-2H-isothiazol-3-one [EC no. 220-239-6] (3:1)

**Human - Skin - Severe irritant**

Amount/concentration applied: 0.01 %

**Conclusion/Summary [Product]** : Not available.

## SECTION 11: Toxicological information

### Serious eye damage/eye irritation

Not available.

**Conclusion/Summary [Product]** : Not available.

### Respiratory corrosion/irritation

Not available.

**Conclusion/Summary [Product]** : Not available.

### Respiratory or skin sensitization

Not available.

### Skin

**Conclusion/Summary [Product]** : Not available.

### Respiratory

**Conclusion/Summary [Product]** : Not available.

### Germ cell mutagenicity

Not available.

**Conclusion/Summary [Product]** : Not available.

### Carcinogenicity

It has been observed that the carcinogenic hazard of this product arises when respirable dust is inhaled in quantities leading to significant impairment of particle clearance mechanisms in the lung.

Not available.

**Conclusion/Summary [Product]** : Not available.

### Reproductive toxicity

Not available.

**Conclusion/Summary [Product]** : Not available.

### Specific target organ toxicity (single exposure)

Not available.

### Specific target organ toxicity (repeated exposure)

Not available.

### Aspiration hazard

Not available.

### Information on likely routes of exposure

Not available.

### Potential acute health effects

**Eye contact** : No known significant effects or critical hazards.

**Inhalation** : No known significant effects or critical hazards.

**Skin contact** : No known significant effects or critical hazards.

**Ingestion** : No known significant effects or critical hazards.

### Symptoms related to the physical, chemical and toxicological characteristics

## SECTION 11: Toxicological information

|              |                     |
|--------------|---------------------|
| Eye contact  | : No specific data. |
| Inhalation   | : No specific data. |
| Skin contact | : No specific data. |
| Ingestion    | : No specific data. |

### Delayed and immediate effects as well as chronic effects from short and long-term exposure

#### Short term exposure

|                             |                  |
|-----------------------------|------------------|
| Potential immediate effects | : Not available. |
| Potential delayed effects   | : Not available. |

#### Long term exposure

|                             |                  |
|-----------------------------|------------------|
| Potential immediate effects | : Not available. |
| Potential delayed effects   | : Not available. |

#### Potential chronic health effects

Not available.

|                                     |                                                     |
|-------------------------------------|-----------------------------------------------------|
| <b>Conclusion/Summary [Product]</b> | : Not available.                                    |
| <b>General</b>                      | : No known significant effects or critical hazards. |
| <b>Carcinogenicity</b>              | : No known significant effects or critical hazards. |
| <b>Mutagenicity</b>                 | : No known significant effects or critical hazards. |
| <b>Reproductive toxicity</b>        | : No known significant effects or critical hazards. |

## 11.2 Information on other hazards

### 11.2.1 Endocrine disrupting properties

Not available.

|                                     |                                                                                                                                                                                                                |
|-------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Conclusion/Summary [Product]</b> | : The product does not meet the criteria to be considered as having endocrine disrupting properties according to the criteria set out in either Regulation (EC) No. 1907/2006 or Regulation (EC) No 1272/2008. |
|-------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

### 11.2.2 Other information

Not available.

## SECTION 12: Ecological information

### 12.1 Toxicity

#### Product/ingredient name

titanium dioxide

#### Result

##### **Acute - LC50 - Marine water**

Fish - Mummichog - *Fundulus heteroclitus*  
>1000000 µg/l [96 hours]  
Effect: Mortality

##### **Acute - LC50 - Fresh water**

Crustaceans - Water flea - *Ceriodaphnia dubia* - Neonate  
Age: <24 hours  
3 mg/l [48 hours]  
Effect: Mortality

1,2-benzisothiazol-3(2H)-one

##### **Acute - LC50 - Fresh water**

OECD [Fish, Acute Toxicity Test]  
Fish - Trout - *Onorhynchus Mykiss*  
1.9 mg/l [96 hours]

##### **Acute - EC50**

OECD 202 [Daphnia sp. Acute Immobilization Test and Reproduction Test]  
Daphnia - Daphnia - *Daphnia Magna*  
3.7 mg/l [48 hours]

##### **Acute - EC50 - Marine water**

OECD 201 [Alga, Growth Inhibition Test]

## SECTION 12: Ecological information

Algae - Algae - *Skeletonema Costatum*  
0.36 mg/l [72 hours]

### Acute - NOEC - Marine water

OECD 201 [Alga, Growth Inhibition Test]  
Algae - Algae - *Skeletonema Costatum*  
0.15 mg/l [72 hours]

2-Methyl-1,2-benzisothiazol-3(2H)-one

### Acute - EC50 - Fresh water

US EPA  
Daphnia - Water flea - *Daphnia magna*  
Age: <24 hours  
0.92 ppm [48 hours]  
Effect: Intoxication

### Acute - EC50 - Fresh water

US EPA  
Algae - Green algae - *Pseudokirchneriella subcapitata*  
0.22 ppm [96 hours]  
Effect: Population

### Acute - LC50 - Fresh water

US EPA  
Fish - Rainbow trout, donaldson trout - *Oncorhynchus mykiss* -  
Juvenile (Fledgling, Hatchling, Weanling)  
0.24 ppm [96 hours]  
Effect: Mortality

### Chronic - NOEC

US EPA  
Fish - Fathead minnow - *Pimephales promelas*  
0.16 ppm [32 days]

**Conclusion/Summary [Product]** : Not available.

## 12.2 Persistence and degradability

### Product/ingredient name

1,2-benzisothiazol-3(2H)-one

### Result

EU  
24% [28 days]

**Conclusion/Summary [Product]** : Not available.

| Product/ingredient name      | Aquatic half-life | Photolysis | Biodegradability |
|------------------------------|-------------------|------------|------------------|
| 1,2-benzisothiazol-3(2H)-one | -                 | -          | Inherent         |

## 12.3 Bioaccumulative potential

| Product/ingredient name      | LogP <sub>ow</sub> | BCF | Potential |
|------------------------------|--------------------|-----|-----------|
| 1,2-benzisothiazol-3(2H)-one | -                  | 3.2 | Low       |

## 12.4 Mobility in soil

### Soil/water partition coefficient

| Product/ingredient name               | logK <sub>oc</sub> | K <sub>oc</sub> |
|---------------------------------------|--------------------|-----------------|
| 1,2-benzisothiazol-3(2H)-one          | 1.9                | 73.142          |
| 2-Methyl-1,2-benzisothiazol-3(2H)-one | 1.7                | 52.5063         |

### Results of PMT and vPvM assessment

## SECTION 12: Ecological information

| Product/ingredient name                                                                                                               | PMT | P  | M  | T  | vPvM | vP | vM |
|---------------------------------------------------------------------------------------------------------------------------------------|-----|----|----|----|------|----|----|
| titanium dioxide                                                                                                                      | No  | No | No | No | No   | No | No |
| 1,2-benzisothiazol-3(2H)-one                                                                                                          | No  | No | No | No | No   | No | No |
| reaction mass of: 5-chloro-2-methyl-4-isothiazolin-3-one [EC no. 247-500-7] and 2-methyl-2H-isothiazol-3-one [EC no. 220-239-6] (3:1) | No  | No | No | No | No   | No | No |
| 2-Methyl-1,2-benzisothiazol-3(2H)-one                                                                                                 | No  | No | No | No | No   | No | No |

**Mobility** : Not available.

**Conclusion/Summary** : The product does not meet the criteria to be considered as a PMT or vPvM.

### 12.5 Results of PBT and vPvB assessment

#### Regulation (EC) No. 1907/2006 [REACH]

| Product/ingredient name                                                                                                               | PBT | P   | B   | T  | vPvB | vP  | vB  |
|---------------------------------------------------------------------------------------------------------------------------------------|-----|-----|-----|----|------|-----|-----|
| titanium dioxide                                                                                                                      | No  | No  | No  | No | No   | No  | No  |
| 1,2-benzisothiazol-3(2H)-one                                                                                                          | No  | N/A | No  | No | No   | N/A | No  |
| reaction mass of: 5-chloro-2-methyl-4-isothiazolin-3-one [EC no. 247-500-7] and 2-methyl-2H-isothiazol-3-one [EC no. 220-239-6] (3:1) | No  | N/A | N/A | No | N/A  | N/A | N/A |
| 2-Methyl-1,2-benzisothiazol-3(2H)-one                                                                                                 | No  | N/A | N/A | No | N/A  | N/A | N/A |

#### Regulation (EC) No. 1272/2008 [CLP]

| Product/ingredient name                                                                                                               | PBT | P  | B  | T  | vPvB | vP | vB |
|---------------------------------------------------------------------------------------------------------------------------------------|-----|----|----|----|------|----|----|
| titanium dioxide                                                                                                                      | No  | No | No | No | No   | No | No |
| 1,2-benzisothiazol-3(2H)-one                                                                                                          | No  | No | No | No | No   | No | No |
| reaction mass of: 5-chloro-2-methyl-4-isothiazolin-3-one [EC no. 247-500-7] and 2-methyl-2H-isothiazol-3-one [EC no. 220-239-6] (3:1) | No  | No | No | No | No   | No | No |
| 2-Methyl-1,2-benzisothiazol-3(2H)-one                                                                                                 | No  | No | No | No | No   | No | No |

**Conclusion/Summary** : The product does not meet the criteria to be considered as a PBT or vPvB.

#### Regulation (EC) No. 1272/2008 [CLP]

### 12.6 Endocrine disrupting properties

Not available.

**Conclusion/Summary [Product]** : The product does not meet the criteria to be considered as having endocrine disrupting properties according to the criteria set out in either Regulation (EC) No. 1907/2006 or Regulation (EC) No 1272/2008.

### 12.7 Other adverse effects

No known significant effects or critical hazards.

## SECTION 13: Disposal considerations

### 13.1 Waste treatment methods

#### Product

**Methods of disposal** : The generation of waste should be avoided or minimised wherever possible. Disposal of this product, solutions and any by-products should at all times comply with the requirements of environmental protection and waste disposal legislation and any regional local authority requirements. Dispose of surplus and non-recyclable products via a licensed waste disposal contractor. Waste should not be disposed of untreated to the sewer unless fully compliant with the requirements of all authorities with jurisdiction.

**Hazardous waste** : Within the present knowledge of the supplier, this product is not regarded as hazardous waste, as defined by EU Directive 2008/98/EC.

**European waste catalogue (EWC)** : 080112, 200128

#### Packaging

**Methods of disposal** : The generation of waste should be avoided or minimised wherever possible. Waste packaging should be recycled. Incineration or landfill should only be considered when recycling is not feasible.

**Special precautions** : This material and its container must be disposed of in a safe way. Empty containers or liners may retain some product residues. Avoid dispersal of spilt material and runoff and contact with soil, waterways, drains and sewers.

## SECTION 14: Transport information

|                                 | ADR/RID        | ADN            | IMDG           | IATA           |
|---------------------------------|----------------|----------------|----------------|----------------|
| 14.1 UN number or ID number     | Not regulated. | Not regulated. | Not regulated. | Not regulated. |
| 14.2 UN proper shipping name    | -              | -              | -              | -              |
| 14.3 Transport hazard class(es) | -              | -              | -              | -              |
| 14.4 Packing group              | -              | -              | -              | -              |
| 14.5 Environmental hazards      | No.            | No.            | No.            | No.            |

**14.6 Special precautions for user** : **Transport within user's premises:** always transport in closed containers that are upright and secure. Ensure that persons transporting the product know what to do in the event of an accident or spillage.

**14.7 Maritime transport in bulk according to IMO instruments** : Not relevant/applicable due to nature of the product.

## SECTION 15: Regulatory information

### 15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

#### EU Regulation (EC) No. 1907/2006 (REACH)

##### Annex XIV - List of substances subject to authorisation

##### Annex XIV

None of the components are listed.

##### Substances of very high concern

None of the components are listed.

## SECTION 15: Regulatory information

### Annex XVII - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles

Labelling :

#### Other EU regulations

Industrial emissions (integrated pollution prevention and control) - Air : Not listed

Industrial emissions (integrated pollution prevention and control) - Water : Not listed

Explosive precursors : Not applicable.

#### Ozone depleting substances (EU 2024/590)

Not listed.

#### Prior Informed Consent (PIC) (649/2012/EU)

Not listed.

#### Persistent Organic Pollutants

Not listed.

#### Seveso Directive

This product is not controlled under the Seveso Directive.

#### International regulations

##### Chemical Weapon Convention List Schedules I, II & III Chemicals

Not listed.

##### Montreal Protocol

Not listed.

##### Stockholm Convention on Persistent Organic Pollutants

Not listed.

##### Rotterdam Convention on Prior Informed Consent (PIC)

Not listed.

##### UNECE Aarhus Protocol on POPs and Heavy Metals

Not listed.

**15.2 Chemical safety assessment** : This product contains substances for which Chemical Safety Assessments are still required.

## SECTION 16: Other information

🔍 Indicates information that has changed from previously issued version.

#### **Abbreviations and acronyms**

: ATE = Acute Toxicity Estimate  
CLP = Classification, Labelling and Packaging Regulation [Regulation (EC) No. 1272/2008]  
DMEL = Derived Minimal Effect Level  
DNEL = Derived No Effect Level  
EUH statement = CLP-specific Hazard statement  
N/A = Not available  
PBT = Persistent, Bioaccumulative and Toxic  
PNEC = Predicted No Effect Concentration  
RRN = REACH Registration Number  
SGG = Segregation Group  
vPvB = Very Persistent and Very Bioaccumulative

#### **Procedure used to derive the classification according to Regulation (EC) No. 1272/2008 [CLP/GHS]**

Not classified.

## SECTION 16: Other information

### Full text of abbreviated H statements

|        |                                                       |
|--------|-------------------------------------------------------|
| H301   | Toxic if swallowed.                                   |
| H302   | Harmful if swallowed.                                 |
| H310   | Fatal in contact with skin.                           |
| H312   | Harmful in contact with skin.                         |
| H314   | Causes severe skin burns and eye damage.              |
| H315   | Causes skin irritation.                               |
| H317   | May cause an allergic skin reaction.                  |
| H318   | Causes serious eye damage.                            |
| H330   | Fatal if inhaled.                                     |
| H351   | Suspected of causing cancer.                          |
| H400   | Very toxic to aquatic life.                           |
| H410   | Very toxic to aquatic life with long lasting effects. |
| H411   | Toxic to aquatic life with long lasting effects.      |
| EUH071 | Corrosive to the respiratory tract.                   |

### Full text of classifications [CLP/GHS]

|                   |                                                 |
|-------------------|-------------------------------------------------|
| Acute Tox. 2      | ACUTE TOXICITY - Category 2                     |
| Acute Tox. 3      | ACUTE TOXICITY - Category 3                     |
| Acute Tox. 4      | ACUTE TOXICITY - Category 4                     |
| Aquatic Acute 1   | SHORT-TERM (ACUTE) AQUATIC HAZARD - Category 1  |
| Aquatic Chronic 1 | LONG-TERM (CHRONIC) AQUATIC HAZARD - Category 1 |
| Aquatic Chronic 2 | LONG-TERM (CHRONIC) AQUATIC HAZARD - Category 2 |
| Carc. 2           | CARCINOGENICITY - Category 2                    |
| Eye Dam. 1        | SERIOUS EYE DAMAGE/EYE IRRITATION - Category 1  |
| Skin Corr. 1C     | SKIN CORROSION/IRRITATION - Category 1C         |
| Skin Irrit. 2     | SKIN CORROSION/IRRITATION - Category 2          |
| Skin Sens. 1A     | SKIN SENSITISATION - Category 1A                |

**Date of issue/ Date of revision** : 28/07/2025

**Date of previous issue** : 03/10/2022

**Version** : 2

RANCH EXKLUSIV

All variants

### Notice to reader

The information in this SDS is based on the present state of our knowledge and on current laws. The product is not to be used for purposes other than those specified under section 1 without first obtaining written handling instructions. It is always the responsibility of the user to take all necessary steps to fulfil the demands set out in the local rules and legislation. The information in this SDS is meant to be a description of the safety requirements for our product. It is not to be considered a guarantee of the product's properties.

